Key result
Despite more than 3 decades of experience with thrombolytic agents for acute pulmonary embolism, their role in treatment remains uncertain and controversial.
Answers are grounded in this paper and cite their sources.
Despite decades of experience, the role of thrombolytic therapy in treating acute pulmonary embolism remains uncertain and controversial.
IED20006 THE FIRST clinical report of the use of a thrombolytic agent (streptokinase) to treat acute pulmonary embolism (PE) appeared in 1964,1 and the first randomized clinical trial comparing urokinase plus heparin with heparin alone was published in 1970.2 A randomized clinical trial comparing urokinase to streptokinase in the treatment of PE was published in 1974.3 The first report of a third thrombolytic agent, recombinant tissue-type plasminogen activator, in the treatment of acute PE was published by Bounameaux et al4 in 1985. The US Food and Drug Administration approved streptokinase in 1977, urokinase in 1978, and recombinant tissuetype plasminogen activator in 1990 for the treatment of acute PE.5 Despite more than 3 decades of experience with these thrombolytic agents, their role in the treatment of PE remains uncertain and controversial.
No takes yet. Share an insight, caveat, or question.
James E. Dalen (2002) conducted a review in Acute pulmonary embolism (PE). Thrombolytic therapy was evaluated. Despite more than 3 decades of experience with thrombolytic agents for acute pulmonary embolism, their role in treatment remains uncertain and controversial.
Synapse has enriched 10 related papers. Consider them for comparative context: